© 2019 Emily Mullin

  • Grey Twitter Icon
  • Grey LinkedIn Icon

I am a staff writer for OneZero, Medium's new technology and science publication, where I write about biotechnology. I have covered topics like gene therapy, CRISPR, consumer genetics, reproductive technology, brain implants, regenerative medicine, biohacking, and AI in medicine. In my work, I seek to illuminate the human side of scientific advances, exploring both the tremendous benefits and unintended consequences of biomedical innovation.

 

Previously, I served as associate editor for biomedicine at MIT Technology Review. ​There, my enterprise reporting uncovered original stories about a fertility startup advertising an unproven "three-parent" IVF technique, a dubious CRISPR trial in Mexico to treat lung cancer patients, and the first commercial use of a landmark gene therapy a year after its approval. While at Tech Review, I won a Newsbrief Award from the D.C. Science Writers Association for my story about a menstrual cycle-on-a-chip.

​My stories have been published by The Washington Post, The Wall Street Journal, Scientific American, National Geographic, The Atlantic, Science, Quartz, Pacific Standard, and The Baltimore Sun, among others. I've also been a contributor at Forbes

 

I started my career as a reporter at the Baltimore Business Journal, where I followed the high-profile case of a Maryland cardiologist accused of implanting unnecessary heart stents in patients. I earned my bachelor's degree in journalism at Ohio University and a master's in science writing from Johns Hopkins University, where I now teach. I hail from the scenic Laurel Highlands of Western Pennsylvania and currently live in Baltimore, Maryland.